DDInter833 DDInter481
Glycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patients, the cancer eventually progresses to become resistant to existing therapies. This warrants further treatment. The goal of treatment with darolutamide is to delay the progression of prostate cancer to metastatic disease, increasing quality of life and life expectancy for those with advanced prostate cancer.[A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Phenylbutazone
Phenylbutazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darolutamide
Glycerol phenylbutyrate {u} (Compound) resembles {v} (Compound) Alverine
Alverine {u} (Compound) resembles {v} (Compound) Propafenone
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Delavirdine
Delavirdine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Glycerol phenylbutyrate {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Phenytoin
Phenytoin {u} may lead to a major life threatening interaction when taken with {v} Darolutamide
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Glycerol phenylbutyrate (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide
Glycerol phenylbutyrate (Compound) resembles Alverine (Compound) and Alverine (Compound) resembles Propafenone (Compound) and Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Glycerol phenylbutyrate (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Delavirdine (Compound) and Delavirdine may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Glycerol phenylbutyrate (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Darolutamide